Clinical Trial: A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07481981) titled 'A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)' on March 13.

Brief Summary: The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.

Study Start Date: April 17

Study Type: INTERVENTIONAL

Condition: Pulmonary Arterial Hypertension

Intervention: DRUG: Treprostinil Palmitil Inhalation Powder

Oral inhalation using a capsule-based dry powder inhaler device.

DRUG: Placebo

Oral inhalation using a capsul...